EUVIMEDEUVIMED entdecken
Open Access

Diagnostic Utility of CD200 Immunohistochemistry in Distinguishing EBV-Positive Large B-Cell Lymphoma From Classic Hodgkin Lymphoma

Christopher Batuello, Emily F Mason

American Journal of Clinical Pathology · 2023

DOI: 10.1093/ajcp/aqad053 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2023. Verfasst von Christopher Batuello und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, US. Hauptthemen laut MEDLINE: Epstein-Barr Virus Infections, Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse, Antigens, CD. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Epstein-Barr virus–positive large B-cell lymphoma (EBV+ LBCL) is a heterogeneous group of diseases that may resemble classic Hodgkin lymphoma (CHL) both morphologically and immunophenotypically. However, these diseases are treated with different therapies and carry distinct prognoses. We examined CD200 expression by immunohistochemistry in EBV+ LBCL and evaluated its diagnostic utility in the differential diagnosis with CHL.

Methods

CD200 immunohistochemistry was performed on archival material from 20 cases of CHL (11 EBV+, 9 EBV−), 11 cases of EBV+ LBCL, and 10 cases of diffuse large B-cell lymphoma, not otherwise specified (DLBCL NOS). Staining pattern and intensity (0-3+ scale) were recorded.

Results

CD200 positivity was seen in Reed-Sternberg cells in 19 (95%) of 20 cases of CHL, predominantly in a strong (3+, 15/19) and diffuse (>50% of cells, 17/19) pattern. In contrast, CD200 was negative in 8 (73%) of 11 cases of EBV+ LBCL; the 3 positive cases showed 1 to 2+ staining in less than 50% of lesional cells. All cases of DLBCL NOS were negative for CD200.

Conclusions

CD200 may be a useful immunophenotypic marker in differentiating EBV+ LBCL from CHL, with negative to partial/weak staining favoring a diagnosis of EBV+ LBCL and strong diffuse staining favoring a diagnosis of CHL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epstein-Barr Virus InfectionsHodgkin DiseaseLymphoma, Large B-Cell, DiffuseAntigens, CDHumansHerpesvirus 4, HumanImmunohistochemistry

Stichwörter der Autor:innen

CD200Classic Hodgkin lymphomaEBVLarge B-cell lymphoma

Substanzen

antigens, CD200Antigens, CD

Autor:innen und Institutionen

  • Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, US.

Förderung

  • NCI NIH HHS
  • NIH HHS
  • NCATS NIH HHS
  • National Center for Advancing Translational Sciences
  • National Institutes of Health
  • National Cancer Institute
  • Shared Instrumentation

Zitieren

APA

Batuello, C., & Mason, E. F. (2023). Diagnostic Utility of CD200 Immunohistochemistry in Distinguishing EBV-Positive Large B-Cell Lymphoma From Classic Hodgkin Lymphoma. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqad053

Vancouver

Batuello C, Mason EF. Diagnostic Utility of CD200 Immunohistochemistry in Distinguishing EBV-Positive Large B-Cell Lymphoma From Classic Hodgkin Lymphoma. American Journal of Clinical Pathology. 2023. doi:10.1093/ajcp/aqad053

BibTeX
@article{Batuello2023,
  author = {Batuello, Christopher and Mason, Emily F},
  title = {Diagnostic Utility of CD200 Immunohistochemistry in Distinguishing EBV-Positive Large B-Cell Lymphoma From Classic Hodgkin Lymphoma},
  journal = {American Journal of Clinical Pathology},
  year = {2023},
  doi = {10.1093/ajcp/aqad053}
}
Kostenlos starten →